Sangamo Therapeutics (SGMOQ) Common Equity (2010 - 2025)

Sangamo Therapeutics' Common Equity history runs 16 years deep, the most recent figure standing at -$14.3 million for Q4 2025.

• On a quarterly basis, Common Equity fell 162.66% year-over-year to -$14.3 million in Q4 2025; TTM through Dec 2025 was -$14.3 million, a 162.66% decrease from a year earlier, with the FY2025 full-year figure at -$14.3 million, down 162.66% from the prior year.
• Common Equity retreated to -$14.3 million in Q4 2025 per SGMOQ's latest filing, from $6.2 million in the prior quarter.
• Across five years, Common Equity topped out at $469.4 million in Q1 2021 and bottomed at -$14.3 million in Q4 2025.
• The 5-year median for Common Equity is $184.3 million (2023), against an average of $194.9 million.
• Across the five-year window, Common Equity advanced 19.02% in 2021 and plunged 162.66% in 2025, its largest moves.
• Year by year, Common Equity stood at $375.3 million in 2021, then fell by 21.42% to $295.0 million in 2022, then sank by 71.9% to $82.9 million in 2023, then plunged by 72.53% to $22.8 million in 2024, then tumbled by 162.66% to -$14.3 million in 2025.
• Per Business Quant, the three latest SGMOQ Common Equity figures stand at -$14.3 million (Q4 2025), $6.2 million (Q3 2025), and $19.6 million (Q2 2025).